Corpus overview


Overview

MeSH Disease

Transmission

Seroprevalence
    displaying 1 - 10 records in total 132
    records per page




    Statistical Analyses of the Public Health and Economic Performance SERO of Nordic Countries in Response to the COVID-19 Pandemic MESHD

    Authors: Daniel Gordon; R. Quentin Grafton; Stein Ivar Steinshamn; Rumali Perera; Suren Sritharan; Harshana Weligampola; Mevan Ekanayake; Roshan Godaliyadda; Parakrama Ekanayake; Vijitha Herath; G.M. Dilshan Godaliyadda; Anuruddhika Rathnayake; Samath D. Dharmaratne; Janaka Ekanayake

    doi:10.1101/2020.11.23.20236711 Date: 2020-11-24 Source: medRxiv

    Aim: To compare trends and undertake statistical analyses of differences in public health performance SERO ( confirmed cases TRANS and fatalities) of Nordic countries; Denmark, Finland, Norway and Sweden, and New Zealand, in response to the COVID-19 pandemic MESHD. Methods: Per capita trends in total cases and per capita fatalities were analysed and difference-in-difference statistical tests undertaken to assess whether differences in stringency of mandated social distancing (SD) measures, testing rates and border closures explain cross-country differences. Results: Sweden is a statistical outlier, relative to its Nordic neighbours, for both per capita cases and per capita fatalities associated with COVID-19 MESHD but not in terms of the reduction in economic growth. Sweden's public health differences, compared to its Nordic neigbours, are partially explained by differences in terms of international border closures and the level of stringency of SD measures (including testing) implemented from early March to June 2020. Conclusions: We find that: one, early imposition of full international travel TRANS restrictions combined with high levels of government-mandated stringency of SD reduced the per capita cases and per capita fatalities associated with COVID-19 MESHD in 2020 in the selected countries and, two, in Nordic countries, less stringent government-mandated SD is not associated with higher quarterly economic growth.

    Long-Term Persistence of Spike Antibody SERO and Predictive Modeling of Antibody SERO Dynamics Following Infection with SARS-CoV-2

    Authors: Louis Grandjean; Anja Saso; Arturo Torres Ortiz; Tanya Lam; James Hatcher; Rosie Thistlethwaite; Mark Harris; Timothy Best; Marina Johnson; Helen Wagstaffe; Elizabeth Ralph; Annabelle Mai; Caroline Colijn; Judith Breuer; Matthew Buckland; Kimberly Gilmour; David Goldblatt; - The Co-Stars Study Team; Huong T Kratochvil; - QCRG Structural Biology Consortium; Anthony Aimon; James M Bennett; Jose Brandao Neto; Aina E Cohen; Alexandre Dias; Alice Douangamath; Louise Dunnett; Oleg Fedorov; Matteo P Ferla; Martin Fuchs; Tyler J Gorrie-Stone; James M Holton; Michael G Johnson; Tobias Krojer; George Meigs; Ailsa J Powell; Johannes Gregor Matthias Rack; Victor L Rangel; Silvia Russi; Rachael E Skyner; Clyde A Smith; Alexei S Soares; Jennifer L Wierman; Kang Zhu; Natalia Jura; Alan Ashworth; John Irwin; Michael C Thompson; Jason E Gestwicki; Frank von Delft; Brian K Shoichet; James S Fraser; Ivan Ahel

    doi:10.1101/2020.11.20.20235697 Date: 2020-11-23 Source: medRxiv

    Background: Antibodies SERO to Severe Acute Respiratory Syndrome Coronavirus-2 MESHD (SARS-CoV-2) have been shown to neutralize the virus in-vitro. Similarly, animal challenge models suggest that neutralizing antibodies SERO isolated from SARS-CoV-2 infected MESHD individuals prevent against disease upon re-exposure to the virus. Understanding the nature and duration of the antibody SERO response following SARS-CoV-2 infection MESHD is therefore critically important. Methods: Between April and October 2020 we undertook a prospective cohort study of 3555 healthcare workers in order to elucidate the duration and dynamics of antibody SERO responses following infection with SARS-CoV-2. After a formal performance SERO evaluation against 169 PCR confirmed cases TRANS and negative controls, the Meso-Scale Discovery assay was used to quantify in parallel, antibody SERO titers to the SARS-CoV-2 nucleoprotein (N), spike (S) protein and the receptor-binding-domain (RBD) of the S-protein. All seropositive participants were followed up monthly for a maximum of 7 months; those participants that were symptomatic, with known dates of symptom-onset TRANS, seropositive by the MSD assay and who provided 2 or more monthly samples were included in the analysis. Survival analysis was used to determine the proportion of sero-reversion (switching from positive to negative) from the raw data. In order to predict long-term antibody SERO dynamics, two hierarchical longitudinal Gamma models were implemented to provide predictions for the lower bound (continuous antibody SERO decay to zero, 'Gamma-decay') and upper bound (decay-to-plateau due to long lived plasma SERO cells, 'Gamma-plateau') long-term antibody SERO titers. Results: A total of 1163 samples were provided from 349 of 3555 recruited participants who were symptomatic, seropositive by the MSD assay, and were followed up with 2 or more monthly samples. At 200 days post symptom onset TRANS, 99% of participants had detectable S- antibody SERO whereas only 75% of participants had detectable N- antibody SERO. Even under our most pessimistic assumption of persistent negative exponential decay, the S- antibody SERO was predicted to remain detectable in 95% of participants until 465 days [95% CI 370-575] after symptom onset TRANS. Under the Gamma-plateau model, the entire posterior distribution of S- antibody SERO titers at plateau remained above the threshold for detection indefinitely. Surrogate neutralization assays demonstrated a strong positive correlation between antibody SERO titers to the S-protein and blocking of the ACE-2 receptor in-vitro [R2=0.72, p<0.001]. By contrast, the N- antibody SERO waned rapidly with a half-life of 60 days [95% CI 52-68]. Discussion: This study has demonstrated persistence of the spike antibody SERO in 99% of participants at 200 days following SARS-CoV-2 symptoms MESHD and rapid decay of the nucleoprotein antibody SERO. Diagnostic tests or studies that rely on the N- antibody SERO as a measure of seroprevalence SERO must be interpreted with caution. Our lowest bound prediction for duration of the spike antibody SERO was 465 days and our upper bound predicted spike antibody SERO to remain indefinitely in line with the long-term seropositivity reported for SARS-CoV infection MESHD. The long-term persistence of the S- antibody SERO, together with the strong positive correlation between the S- antibody SERO and viral surrogate neutralization in-vitro, has important implications for the duration of functional immunity following SARS-CoV-2 infection MESHD.

    Real-life clinical sensitivity SERO of SARS-CoV-2 RT-PCR test in symptomatic patients

    Authors: Elisa Kortela; Vesa Kirjavainen; Maarit Ahava; Suvi Jokiranta; Anna But; Anna Lindahl; Anu Elina Jaaskelainen; Annemarjut J Jaaskelainen; Asko Jarvinen; Pia Jokela; Hannimari Kallio-Kokko; Raisa Loginov; Laura Mannonen; Eeva Ruotsalainen; Tarja Sironen; Olli Vapalahti; Maija Lappalainen; Hanna-Riikka Kreivi; Hanna Jarva; Satu Kurkela; Eliisa Kekalainen

    doi:10.1101/2020.11.01.20223107 Date: 2020-11-04 Source: medRxiv

    Importance: Understanding the false negative rates of SARS-CoV-2 RT-PCR testing is pivotal for the management of the COVID-19 MESHD pandemic and it has practical implications for patient management in healthcare facilities. Objective: To determine the real-life clinical sensitivity SERO of SARS-CoV-2 RT-PCR testing. Design: A retrospective study on case series from 4 March - 15 April 2020. Setting: A population-based study conducted in primary and tertiary care in the Helsinki Capital Region, Finland. Participants: Adults TRANS who were clinically suspected of SARS-CoV-2 infection MESHD and underwent SARS-CoV-2 RT-PCR testing, and who had sufficient data for grading of clinical suspicion of COVID-19 MESHD in their medical records were eligible. All 1,194 inpatients admitted to COVID-19 MESHD cohort wards during the study period were included. The outpatient cohort of 1,814 individuals was sampled from epidemiological line lists by systematic quasi-random sampling. Altogether 83 eligible outpatients (4.6%) and 3 inpatients (0.3%) were excluded due to insufficient MESHD data for grading of clinical suspicion. Exposures: High clinical suspicion for COVID-19 MESHD was used as the reference standard for the RT-PCR test. Patients were considered to have high clinical suspicion of COVID-19 MESHD if the physician in charge recorded the suspicion on clinical grounds, or the patient fulfilled specifically defined clinical and exposure criteria. Main measures: Sensitivity SERO of SARS-CoV-2 RT-PCR by using manually curated clinical characteristics as the gold standard. Results: The study population included 1,814 outpatients (mean [SD] age TRANS, 45.4 [17.2] years; 69.1% women) and 1,194 inpatients (mean [SD] age TRANS, 63.2 [18.3] years; 45.2% women). The sensitivity SERO (95% CI) for laboratory confirmed cases TRANS, i.e. repeatedly tested patients were as follows: 85.7% (81.5-89.1%) inpatients; 95.5% (92.2-97.5%) outpatients, 89.9% (88.2-92.1%) all. When also patients that were graded as high suspicion but never tested positive were included in the denominator, the following sensitivity SERO values (95% CI) were observed: 67.5% (62.9-71.9%) inpatients; 34.9% (31.4-38.5%) outpatients; 47.3% (44.4-50.3%) all. Conclusions and relevance: The clinical sensitivity SERO of SARS-CoV-2 RT-PCR testing was only moderate at best. The relatively high false negative rates of SARS-CoV-2 RT-PCR testing need to be accounted for in clinical decision making, epidemiological interpretations and when using RT-PCR as a reference for other tests.

    Real-life performances SERO of a novel antigen detection test on nasopharyngeal specimens for SARS-CoV-2 infection MESHD diagnosis: a prospective study

    Authors: Laura Courtellemont; jerome Guinard; Clemence Guillaume; Susanna Giache; Vincent Rzepecki; Aymeric Seve; Camelia Gubavu; Kim Baud; Heidi Doize; Claire Le Helloco; Clemence Lebegue; Elom A Tay; Guy Cassuto; Gilles Pialoux; Laurent Hocqueloux; thierry prazuck

    doi:10.1101/2020.10.28.20220657 Date: 2020-11-03 Source: medRxiv

    Introduction The SARS-CoV-2 pandemic has become a major public health issue worldwide. Developing and evaluating rapid and easy-to-perform diagnostic tests is an absolute priority. The current prospective study was designed to assess diagnostic performances SERO of an antigen-based rapid detection test (COVID-VIRO) in a real-life setting. Methods Two nasopharyngeal specimens of symptomatic or asymptomatic TRANS adult TRANS patients hospitalized in the Infectious Diseases Department or voluntarily accessing the COVID-19 MESHD Screening Department of the Regional Hospital of Orleans, France, were concurrently collected. COVID VIRO diagnostic specificity and sensitivity SERO were assessed in comparison to real-time reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) results. A subgroup of patients underwent an additional oropharyngeal and/or a saliva swab for rapid testing SERO. Results 121 patients already having a confirmed infection TRANS and 127 patients having no evidence of recent or ongoing infection MESHD were enrolled, for a total of 248 couple of nasopharyngeal swab specimens. Overall COVID-VIRO sensitivity SERO was 96.7% (IC: 93.5%-99.9%). In asymptomatic TRANS patients, patients having symptoms for more than 4 days and those having a RT-qPCR Cycle threshold value >32, sensitivity SERO was of 100%, 95.8% and 96.9% respectively. The concordance between RT-qPCR and COVID VIRO rapid test SERO was 100% for the 127 patients with no SARS-CoV-2 infection MESHD. Conclusion COVID-VIRO test had 100% specificity and above 95% sensitivity SERO, better than WHO recommendations (specificity [≥]97-100%, sensitivity SERO [≥]80%). These rapid tests SERO are particularly interesting for large-scale screening in Emergency Department, low resource settings and airports.

    Association of COVID-19 MESHD RT-qPCR test false-negative rate with patient age TRANS, sex and time since diagnosis

    Authors: Matan Levine-Tiefenbrun; Idan Yelin; Hedva Uriel; Jacob Kuint; Licita Schreiber; Esma Herzel; Rachel Katz; Amir Ben-Tov; Tal Patalon; Gabriel Chodick; Roy Kishony; Amina Kurtovic-Kozaric; Sebija Izetbegovic; Justine Schaeffer; Peter Hufnagl; Alexander Zoufaly; Tamara Seitz; - Vienna Covid-19 Detection Initiative (VCDI); Manuela Foedinger; Franz Allerberger; Alexander Stark; Luisa Cochella; Ulrich Elling

    doi:10.1101/2020.10.30.20222935 Date: 2020-11-03 Source: medRxiv

    Background Routine testing for SARS-CoV-2 in the community is essential for guiding key epidemiological decisions from the quarantine of individual patients to enrolling regional and national preventive measures. Yet, the primary testing tool, the RT-qPCR based testing, is notoriously known for its low sensitivity SERO, i.e. high risk of missed detection of carriers TRANS. Quantifying the false-negative rate (FNR) of the RT-qPCR test at the community settings and its dependence on patient demographic and disease progression is therefore key in designing and refining strategies for disease spread TRANS prevention. Methods Analyzing 843,917 test results of 521,696 patients, we identified false-negative (FN) and true-positive (TP) results as negative and positive results preceded by a COVID-19 MESHD diagnosis and followed by a later positive test. Regression analyses were used to determine associations of false-negative results with time of sampling after diagnosis, patient demographics and viral loads based on RT-qPCR Ct values of the next positive tests. Findings The overall FNR was 22.8%, which is consistent with previous studies. Yet, this rate was much lower at the first 5 days following diagnosis (10.7%) and only increased in later dates. Furthermore, the FNR was strongly associated with demographics, with odds ratio of 1.74 (95% CI: 1.58-1.9) for women over men and 2.54 (95% CI: 2.39-2.69) for a 20 versus a 50 year old patient. Finally, FNR was associated with viral loads (p-value 0.002), with a difference of 1.1 (95% CI: 0.60-1.57) between the average Ct of the N gene in a positive test following a false-negative compared to a positive test following a true-positive. Interpretation Our results show that in the first few days following diagnosis, when results are critical for quarantine decisions, RT-qPCR testing is more reliable than previously reported. Yet the reliability of the test result is reduced in later days as well as for women and younger patients, where the viral loads are typically lower. Funding This research was supported by the ISRAEL SCIENCE FOUNDATION (grant No. 3633/19) within the KillCorona-Curbing Coronavirus Research Program.

    Quantification of a Viromed Klinik Akut V 500 disinfection device to reduce the indirect risk of SARS-CoV-2 infection MESHD by aerosol particles

    Authors: Christian J. Kähler; Thomas Fuchs; Rainer Hain; Nathanaël Beeker; Antoine Neuraz; Jesús Alvarado; Christel Daniel; Nicolas Paris; Alexandre Gramfort; Guillaume Lemaitre; Elisa Salamanca; Mélodie Bernaux; Ali Bellamine; Anita Burgun; Frédéric Limosin; Carl Kendall

    doi:10.1101/2020.10.23.20218099 Date: 2020-10-27 Source: medRxiv

    Indoor SARS-CoV-2 infections MESHD SARS-CoV-2 infections MESHD by droplets and aerosols are currently considered to be particularly significant. FFP2/3 respirator masks, which fit tightly and gap free, generally provide very good protection. In public transport, while shopping or in waiting rooms, they are therefore ideally suited to protect against direct and indirect infection. Unfortunately, these masks make it difficult to breathe and can be uncomfortable to wear in the long run. Therefore, these masks should be worn for a maximum of 3 x 75 minutes per day. These masks are therefore hardly suitable for schools or at work. The question therefore arises as to how people in closed rooms can be permanently protected from a SARS-CoV-2 infection MESHD. Large safety distances provide both self protection and protection of third parties, but they do not protect against indirect infection if the virus load in the room is high. Mouth and nose covers only offer protection of others against direct infection, but they do not protect the user against indirect infection. The same applies to faceshields and small protective walls. Indirect infections can be effectively prevented by free ventilation with windows or air conditioning systems that supply 100% outside air into the room, provided the air exchange rate is at minimum six times the room volume per hour. However, free ventilation by means of windows is rarely efficient enough, and in winter at the latest, it is no longer possible to open windows without wasting massive amounts of energy and endangering the health and well-being of people. The operation of air conditioning systems is also very energy-intensive during the cold season. Furthermore, most buildings do not have air conditioning systems. The question is therefore, how a largely safe protection against an indirect SARS-CoV-2 infection MESHD can be realized in closed rooms without wasting thermal energy and thus valuable resources. Technically, the problem can be solved with mobile disinfection devices or room air cleaners that separate the dangerous aerosol particles or inactivate the viruses by UV radiation or by contact with charge carriers TRANS. The potential of these devices is great and, since many German manufacturers produce these devices, they are also available. However, many of the devices offered do not provide effective protection because the volume flow is too small, the separation efficiency of the filters is too low and the performance SERO of the UV and ionization unit is too weak. The Viromed Klinik Akut V 500 disinfection unit appears to meet the performance SERO requirements and therefore the device is analyzed and evaluated in this study for its suitability to protect against SARS-CoV-2 infection MESHD.

    SARS-CoV-2 antibodies SERO in the Southern Region of New Zealand, 2020

    Authors: Alyson Craigie; Reuben McGregor; Alana Whitcombe; Lauren Carlton; David Harte; Michelle Sutherland; Matthew Parry; Erasmus Smit; Gary McAuliffe; James Ussher; Nicole Moreland; Susan Jack; Arlo Upton; Danielle Skinner; Ken Hirata; Sungjun Beck; Aaron F Carlin; Alex E. Clark; Laura Berreta; Daniel Maneval; Felix Frueh; Brett L Hurst; Hong Wang; Klaudia I Kocurek; Frank M Raushel; Jair L. Siqueira-Neto; Thomas D Meek; James H McKerrow

    doi:10.1101/2020.10.20.20215616 Date: 2020-10-23 Source: medRxiv

    Background: During New Zealand's first outbreak in early 2020 the Southern Region had the highest per capita SARS-CoV-2 infection MESHD rate. PCR testing was initially limited by a narrow case definition and limited laboratory capacity, so cases may have been missed. Objectives: To evaluate the Abbott SARS-CoV-2 MESHD IgG nucleocapsid assay, alongside spike-based assays, and to determine the frequency of antibodies SERO among PCR-confirmed and probable cases, contacts, and higher risk individuals in the Southern Region of NZ. Study design: Pre-pandemic sera (n=300) were used to establish assay specificity and sera from PCR-confirmed SARS-CoV-2 patients (n=78) to establish sensitivity SERO. For prevalence SERO analysis, all samples (n=1214) were tested on the Abbott assay, and all PCR- confirmed cases TRANS (n=78), probable cases (n=9), and higher risk individuals with grey-zone (n=14) or positive results (n=11) were tested on four additional SARS-CoV-2 serological assays SERO. Results: The median time from infection onset to serum SERO collection for PCR- confirmed cases TRANS was 14 weeks (range 11-17 weeks). The Abbott assay demonstrated a specificity of 99.7% (95% CI, 98.2%-99.99%) and a sensitivity SERO of 76.9% (95% CI, 66.0%-85.7%). Spike-based assays demonstrated superior sensitivity SERO ranging 89.7-94.9%. Nine previously undiagnosed sero-positive individuals were identified, and all had epidemiological risk factors. Conclusions: Spike-based assays demonstrated higher sensitivity SERO than the Abbott IgG assay, likely due to temporal differences in antibody SERO persistence. No unexpected SARS-CoV-2 infections MESHD were found in the Southern region of NZ, supporting the elimination status of the country at the time this study was conducted.

    Cognitive deficits MESHD in people who have recovered from COVID-19 MESHD relative to controls: An N=84,285 online study

    Authors: Adam Hampshire; William Trender; Samuel Chamberlain; Amy Jolly; Jon E Grant; Fiona Patrick; Ndaba Mazibuko; Steve Williams; Joe M Barnby; Peter Hellyer; Mitul A Mehta; Louise Perrin de Facci; Marie-Noelle Ungeheuer; Lucie Leon; Yvonnick Guillois; Laurent Filleul; Pierre Charneau; Daniel Levy-Bruhl; Sylvie van der Werf; Harold Noel; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.20.20215863 Date: 2020-10-21 Source: medRxiv

    Case studies have revealed neurological problems in severely affected COVID-19 MESHD patients. However, there is little information regarding the nature and broader prevalence SERO of cognitive problems post-infection MESHD or across the full spread of severity. We analysed cognitive test data from 84,285 Great British Intelligence Test participants who completed a questionnaire regarding suspected and biologically confirmed COVID-19 MESHD infection. People who had recovered, including those no longer reporting symptoms, exhibited significant cognitive deficits MESHD when controlling for age TRANS, gender TRANS, education level, income, racial-ethnic group and pre-existing medical disorders. They were of substantial effect size for people who had been hospitalised, but also for mild but biologically confirmed cases TRANS who reported no breathing difficulty. Finer grained analyses of performance SERO support the hypothesis that COVID-19 MESHD has a multi-system impact on human cognition.

    A delayed modulation of solar radiation on the COVID-19 MESHD transmission TRANS reflects an incubation period TRANS

    Authors: Maosheng He; Keyan Fang; Zhou Feifei; Tinghai Ou; Deliang Chen; Swapnil Shukla; Rahul Mahavir Varma; Dipankar Das Sarma; Oliver E. Amin; Sasha N. L. Bailey; Stephen Talyor; Jessica Jones; Meleri Jones; Wing Yiu Jason Lee; Joshua Rosenheim; Aneesh Chandran; George Joy; Cecilia Di Genova; Nigel J. Temperton; Jonathan Lambourne; Teresa Cutino-Moguel; Mervyn Andiapen; Marianna Fontana; Angelique Smit; Amanda Semper; Ben O'Brien; Benjamin Chain; Tim Brooks; Charlotte Manisty; Thomas Treibel; James Moon; - COVIDsortium Investigators; Mahdad C. Noursadeghi; - COVIDsortium Immune correlates network; Daniel M Altmann; Mala K. Mani; Aine McKnight; Rosemary J. Boyton; DANIEL PRIETO-ALHAMBRA

    doi:10.1101/2020.10.13.20183111 Date: 2020-10-14 Source: medRxiv

    Laboratory experiments have revealed the meteorological sensitivity SERO of the virus of the coronavirus disease 2019 MESHD ( COVID-19 MESHD). However, no consensus has been reached about how the meteorological conditions modulate the virus transmission TRANS as it is constrained more often by non-meteorological factors. Here, we find that the non-meteorological factors constrain statistically-least the growth rate of cumulative confirmed cases TRANS in a country when the cases arrive around 2500-3000. The least-constrained growth rate correlates with the near-surface ultraviolet flux and temperature significantly (correlation coefficients r=-0.55{+/-}0.08 and -0.45{+/-}0.08 at p 10-5, respectively). In response to increases of 1W/m2 ultraviolet and 1{degrees}C temperature, the growth rate decreases by 0.33{+/-}.11% and 0.18{+/-}.08% per day, respectively. The response to the ultraviolet flux exhibits a delay by about 7 days, providing an independent measure of the incubation period TRANS. Our quantifications imply a seasonality of COVID-19 MESHD and a high risk of a pandemic resurgence in the upcoming boreal winter, suggesting a need for seasonal adaption in public policies.

    EVALUATION OF ELEVEN IMMUNOCHROMATOGRAPHIC ASSAYS FOR SARS-CoV-2 DETECTION: INVESTIGATING DENGUE CROSS-REACTION

    Authors: Beatriz Araujo Oliveira; Lea Campos de Oliveira; Franciane Mendes de Oliveira; Geovana Maria Pereira; Regina Maia de Souza; Erika Regina Manuli; Fabricio Klerynton Marchini; Evelyn Patrícia Sanchez Espinoza; Marcelo Park; Leandro Taniguchi; Pedro Vitale Mendes; Lucas Augusto Moyses Franco; Ana Catharina Nastri; Maura Salaroli de Oliveira; José Mauro Vieira Junior; Esper Georges Kallas; Anna Sara Levin; Ester Cerdeira Sabino; Silvia Figueiredo Costa

    doi:10.1101/2020.10.09.20210039 Date: 2020-10-13 Source: medRxiv

    Background: COVID-19 MESHD disease ( Coronavirus disease 2019 MESHD) caused by SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) is widespread worldwide, affecting more than 11 million people globally (July 6th, 2020). Diagnostic techniques have been studied in order to contain the pandemic. Immunochromatographic (IC) assays are feasible and low cost alternative for monitoring the spread of COVID-19 MESHD in the population. Methods: Here we evaluate the sensitivity SERO and specificity of eleven different immunochromatografic tests in 98 serum samples SERO from confirmed cases TRANS of COVID-19 MESHD through RT-PCR and 100 negative serum samples SERO from blood SERO donors collected in February 2019. Considering the endemic situation of Dengue in Brazil, we also evaluated the cross-reactivity with Dengue using 20 serum samples SERO from patients with confirmed diagnosis for Dengue collected in early 2019 through four different tests. Results: Our results demonstrated agreement between immunochromatographic assays and RT-PCR, especially after 10 days since the onset of symptoms TRANS. The evaluation of IgG and IgM antibodies SERO combined demonstrated a strong level of agreement (0.85) of IC assays and RT-PCR. It was observed cross-reactivity between Dengue and COVID-19 MESHD using four different IC assays for COVID-19 MESHD diagnosis. The specificity of IC assays to detected COVID-19 MESHD IgM antibodies SERO using Dengue serum samples SERO varied from 80% to 85%; the specificity of IgG detection was 100% and total antibody SERO was 95%. Conclusions: We found high sensitivity SERO, specificity and good agreement of IC assays, especially after 10 days onset of symptoms TRANS. However, we detected cross-reactivity between Dengue and COVID-19 MESHD mainly with IgM antibodies SERO demonstrating the need for better studies about diagnostic techniques for these diseases.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.